In alignment with its strategic focus on spinal fixation and deformity correction, Orthofix has announced the discontinuation of its M6-C™ artificial cervical disc and M6-L™ artificial lumbar disc product lines. This decision will enable the company to concentrate resources and investments on its core business areas, fostering innovation and long-term growth.
“As we continue to refine our portfolio, our priority is to focus on the areas where we can deliver the greatest impact for surgeons and patients,” said Cary Hagan, President of Global Spine at Orthofix. “Spinal fixation and deformity correction represent strong growth opportunities where we can leverage our expertise to drive meaningful advancements in patient care.”
The M6-C artificial cervical disc is designed to maintain the natural behavior of a functional spinal unit by replicating the biomechanical characteristics of the native disc. Since its introduction, the M6-C has established a robust clinical history, with over 70,000 devices implanted in more than 20 countries. Despite its strong market presence, Orthofix has decided to prioritize product lines with greater long-term growth potential.
In 2024, the M6-C and M6-L artificial discs generated global net sales of $23.4 million. However, as the spinal market evolves, Orthofix has identified greater potential in higher-margin, sustainable segments. By streamlining its offerings, the company aims to enhance operational efficiency and accelerate the development of innovative spine solutions.
Orthofix remains committed to meeting all regulatory and post-market obligations related to the M6 product lines. This includes completing the Investigational Device Exemption (IDE) study in the U.S. and maintaining compliance with ongoing post-market surveillance requirements.
For surgeons and healthcare providers currently using M6 products, Orthofix will ensure a smooth transition by providing continued support and guidance. The company is working closely with its partners to minimize any disruption to patient care.
This strategic shift reflects broader industry trends, where companies are increasingly focusing on their most profitable and differentiated product lines. While the M6 artificial discs have played a role in motion preservation, Orthofix is reinforcing its commitment to spine care by investing in areas with the highest potential for clinical and commercial success.